The outcomes of this research demonstrated that the effective rate of EGFR-TKI in the treatment of NSCLC patients was 26.67%, suggesting that EGFR-TKI has certain clinical efficacy in the therapy of advanced NSCLC (25). Here, EGFR is linked to non-small cell lung carcinoma.